CSIMarket

Zimmer Biomet Holdings, Inc.  (ZMH)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 206
 Employees 10,000
 Revenues (TTM) (Millions $) 5,287
 Net Income (TTM) (Millions $) 197
 Cash Flow (TTM) (Millions $) 500
 Capital Exp. (TTM) (Millions $) 388

Zimmer Biomet Holdings, Inc.
Zimmer Holdings, Inc., a Delaware corporation, is a global leader in the design, development, manufacture and marketing of reconstructive orthopaedic implants, including joint and dental, spinal implants, and trauma products and related orthopaedic surgical products. The Company is headquartered in Warsaw, Indiana.

The Company’s primary customers include musculoskeletal surgeons, neuro-surgeons, oral surgeons, dentists, hospitals, distributors, healthcare dealers and, in their capacity as agents, healthcare purchasing organizations or buying groups. These customers range from large multinational enterprises to independent surgeons. A majority of hospitals in the United States belong to at least one group purchasing organization.

After the acquisition of Centerpulse, the Company now has operations in more than 24 countries and markets products in more than 80 countries, with corporate headquarters in Warsaw, Indiana, and manufacturing, distribution and warehousing and/or office facilities in more than 60 locations worldwide. The Company manages its operations through three major geographic segments – the Americas, which is comprised principally of the United States and includes other North, Central and South American markets; Europe, which is comprised principally of Europe and includes the Middle East and Africa; and Asia Pacific, which is comprised primarily of Japan and includes other Asian and Pacific markets.

The Company sells product through two principal channels: 1) direct to health care institutions, such as hospitals, which is referred to as a direct channel account, and 2) through stocking distributors and, in the Asia Pacific region, healthcare dealers.

Through the direct channel accounts, inventory is generally consigned to sales agents or customers so that products are available when needed for surgical procedures. With the sales to stocking distributors and healthcare dealers, title to product passes generally upon shipment. Products are marketed and sold to all types of Company customers via both direct channel accounts and stocking distributors and healthcare dealers.

The Company designs, develops, manufactures and markets reconstructive orthopaedic implants, including joint and dental, spinal implants, and trauma products, and related orthopaedic surgical products. Orthopaedic reconstructive implants restore joint function lost due to disease or trauma in joints such as knees, hips, shoulders, and elbows.

Dental reconstructive implants restore function and aesthetics in patients that have lost teeth due to trauma or disease. Spinal implants are utilized by orthopaedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities and trauma in all regions of the spine. Trauma products are devices used primarily to reattach or stabilize damaged bone or tissue to support the body’s natural healing process. The Company’s related orthopaedic surgical products include surgical supplies and instruments designed to aid in orthopaedic surgical procedures. The Company also has a limited array of sports medicine products.

As part of its focused research and development efforts and desire to create breakthrough orthopaedic treatments, the Company has established an Orthobiologics group with its own full-time staff and projects. The Company is actively involved in the field of biologics and is committed to investing in biologics research activities, with a short-term focus on developing products for the spine market, such as a CopiOs™ calcium phosphate bone void filler. The Company is working to develop biological materials to repair and reinforce damaged or degenerated tissues. These materials potentially could transform treatment of damaged joints by biological regeneration rather than replacement with inert materials.

Orthobiologics products that are currently marketed for sale include the following: 1) CMI, 2) Collagraft® Bone Graft Matrix, which is a bone void filler material made of HA/ TCP and bovine collagen, and 3) Denovo®-C, which is an autologous cell implantation service for articular cartilage repair. The Company has also publicly announced certain active or pending research and development activities of the Orthobiologics group. For instance, the Company is collaborating with ISTO Technologies on a project to develop a chondral and osteochondral cartilage graft for cartilage tissue repair and regeneration.

The Company is also working with Tissue Science Laboratories plc, a company based in the United Kingdom (“TSL”), with respect to final development and distribution of the Rotator Cuff Repair Patch, an innovative, nonresorbable biological collagen patch for repair of rotator cuff injuries in the shoulder. This product is being developed and manufactured by TSL.

COMPETITION

The orthopaedics industry is highly competitive. In the global markets for reconstructive implants, trauma and orthopaedic surgical products, major competitors include: DePuy Orthopaedics, Inc. (a subsidiary of Johnson & Johnson), Stryker Corp., Biomet, Inc., Synthes-Stratec, Inc. and Smith & Nephew, plc.

In the Americas geographic segment, DePuy Orthopaedics, Inc., Stryker Corp. and Biomet, Inc., along with the Company, account for a large majority of the total reconstructive implant sales.

In the Asia Pacific market for reconstructive implant and trauma products, the Company competes primarily with DePuy Orthopaedics, Inc. and Stryker Corp., as well as regional companies, including Kyocera and MDM. Factors, such as the dealer system, complex regulatory environments and the accompanying inability to compete on price, make it difficult for smaller companies, particularly those that are non-regional, to compete effectively with the market leaders in the Asia Pacific region.

In Europe, the reconstructive implant and trauma product markets are more fragmented than the Americas or the Asia Pacific segments. The variety of philosophies held by European surgeons regarding hip reconstruction, for example, has fostered the existence of many small, niche European companies.

Today most hip implants sold in Europe are products developed specifically for Europe, although global products are gaining acceptance. Therefore, the Company, in addition to its global products, will continue to develop and produce specially tailored products to meet specific European needs. Particularly with the acquisition of Centerpulse, the Company believes it is well positioned in this region in the reconstructive implant market.

In the spinal implant area, the Company competes globally primarily with Medtronic/ Sofamor Danek, Inc. (a subsidiary of Medtronic, Inc.), Synthes-Stratec, Inc., DePuy Spine (a subsidiary of Johnson & Johnson), Stryker Corp., and EBI, L.P. (a subsidiary of Biomet, Inc.).

In the dental reconstructive implant area, the Company competes primarily with Nobel Biocare AB, Straumann AG, and Implant Innovations, Inc. (a subsidiary of Biomet, Inc.).

Competition within the industry is primarily based on technology, innovation, quality, reputation, customer relationships and service. A key factor in the Company’s continuing success in the future will continue to be its ability to develop new products and improve upon existing products and technologies. Where possible, the Company will continue to seek patent, trademark and other intellectual property protection concerning the surgical techniques, materials, technologies and products it designs and develops.



   


Customers Net Income grew by ZMH's Customers Net Profit Margin grew to

25.77 %

1.37 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

Year to Date Decrease / Increase
     
MDT   -3.36%    
PDCO        6.82% 
SYK   -13.48%    
CAH        7.29% 
JNJ        3.17% 
MCK        30.13% 
• View Complete Report
   



Arvana Inc.

Arvana Inc announced financial period ending Mar 31 2022 operating deficit of $-0.008636 millions

In the financial period ending Mar 31 2022 Arvana Inc reached break-even of $0.00 per share compared to $-0.03 a year ago and from $-0.19 per share from the previous quarter.

Nextgen Healthcare Inc.

A modest 4.9%, rise in Sales at Nextgen Healthcare Inc in the financial time-frame ending Mar 31 2022

In the financial time-frame ending Mar 31 2022 Nextgen Healthcare Inc earnings turn positive of $0.01 per share compared to $-0.01 a year ago and eps dropped by -93.58 % from $0.08 per share from the previous quarter.

Peapack gladstone Financial Corporation

Peapack Gladstone Financial Corporation disclosed a moderate 5.21%, increase in their Revenues in the first quarter of 2022 earnings season

Peapack Gladstone Financial Corporation reported solid first quarter of 2022 earnings season, where Revenue grew by 5.21% to $51.96 millions in comparison to $49.39 millions on a year-over-year basis, company posted earnings growth of 5.97 % to $0.71, as comparison at $0.67 in the prior year quarter.

Csw Industrials Inc.

Csw Industrials Inc announced financial time-frame ending Mar 31 2022 operating profit of $30.866 millions

Csw Industrials Inc showed respectable growth in the financial time-frame ending Mar 31 2022, where earnings per share more than doubled by 113.25 % year on year to $1.26 per share and Sales increased by 29.94% to $173.30 millions.

The Teardroppers Inc

The Teardroppers Inc announced a similar performance like a year before in the first quarter of 2022

The Teardroppers Inc announced operating deficit of $-0.103299 millions, in the first quarter of 2022, an advancement from the operating loss of $-0.118515 millions, recorded in the same quarter a year ago.






 

Zimmer Biomet Holdings's Segments
 
Americas
 Segment    64.32 % of total Revenue
Asia Pacific
 Segment    14.39 % of total Revenue
Europe
 Segment    21.29 % of total Revenue
Other
 Segment    4.18 % of total Revenue
Knees
 Segment    35.86 % of total Revenue
Hips
 Segment    24.66 % of total Revenue
Dental
 Segment    5.87 % of total Revenue
Extremeties
 Segment    21.05 % of total Revenue
Reconstructive implants
 Segment    87.44 % of total Revenue
Spine
 Segment    8.38 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Zimmer Biomet Holdings does not provide revenue guidance.

Earnings Outlook
The Teardroppers Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion
Americas 55.51 %
Asia Pacific 17.32 %
Europe 27.16 %


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

NTIP's Profile

Stock Price

NTIP's Financials

Business Description

Fundamentals

Charts & Quotes

NTIP's News

Suppliers

NTIP's Competitors

Customers & Markets

Economic Indicators

NTIP's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071